Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00307294 · ClinicalTrials.gov registry record · Phase 2
Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00307294 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 40 participants.
The verdict
NCT00307294, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate PSA response rates of the combination of Doxil and Thalidomide in patients with AIPC who have failed chemotherapy. Secondary objectives include: 1) To evaluate the clinical response rate of this combination on measurable disease 2) To evaluate overall survival for this combination.
Interventions
- DRUG Doxil
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00307294
The ClinicalTrials.gov registry entry for NCT00307294 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxil is the first listed.
NCT00307294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00307294 about?
NCT00307294 is a clinical study titled "Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)". The primary objective of this study is to evaluate PSA response rates of the combination of Doxil and Thalidomide in patients with AIPC who have failed chemotherapy. Secondary objectives include: 1) To evaluate the clinical response rate of this combination on measurable disease 2) To evaluate overa...
What is the current status of trial NCT00307294?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2006-03. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00307294?
The interventions under investigation include: Doxil (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00307294?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.